Pediatrics international : official journal of the Japan Pediatric Society · 2026
Urinary biomarkers and serum VEGF in preterm infants with retinopathy of prematurity treated with ranibizumab.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nagaoka Mitsuhide, Yoshida Taketoshi, Niimi Hidekazu, Honda Akane, Maeno Seiko, Miyazono Yayoi, Inomata Satomi, Kawasaki Yukako, Tamura Kentaro, Matsumura Kenta
Аннотация
BACKGROUND AND OBJECTIVE: Intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibodies is widely used to treat retinopathy of prematurity (ROP), yet, its systemic effects remain unclear. In adults, intravitreal anti-VEGF therapy has been associated with proteinuria and acute kidney injury. This study aimed to evaluate the renal effects of anti-VEGF antibody (Ranibizumab) by longitudinally measuring urinary biomarkers and serum VEGF levels in preterm infants with ROP.
METHODS: Preterm infants were categorized into two groups based on ROP treatment status: those receiving intravitreal ranibizumab (IVR) (treated group) and age-matched controls without treatment (nontreated group). Urinary biomarkers, including angiotensinogen, liver-type fatty acid-binding protein (L-FABP), albumin, and podocalyxin, were assessed at three time points: before treatment, and at one and 2 months post-IVR. Serum VEGF levels were measured 1 month post-IVR.
RESULTS: The study included 30 infants in the treated group and 12 in the nontreated group. The mean gestational age and birth weight were 24.9 weeks and 664 g in the treated group, and 26.8 weeks and 845.6 g in the nontreated group. The mean postnatal age at treatment was 68.8 days, with a postmenstrual age of 34.8 weeks. No significant differences were observed in urinary biomarker levels between the groups at one and 2 months posttreatment. Serum VEGF levels were higher in the treated group than in the nontreated group after IVR.
CONCLUSION: IVR treatment did not show the sustained renal injury or suppress serum VEGF levels in preterm infants with ROP.
METHODS: Preterm infants were categorized into two groups based on ROP treatment status: those receiving intravitreal ranibizumab (IVR) (treated group) and age-matched controls without treatment (nontreated group). Urinary biomarkers, including angiotensinogen, liver-type fatty acid-binding protein (L-FABP), albumin, and podocalyxin, were assessed at three time points: before treatment, and at one and 2 months post-IVR. Serum VEGF levels were measured 1 month post-IVR.
RESULTS: The study included 30 infants in the treated group and 12 in the nontreated group. The mean gestational age and birth weight were 24.9 weeks and 664 g in the treated group, and 26.8 weeks and 845.6 g in the nontreated group. The mean postnatal age at treatment was 68.8 days, with a postmenstrual age of 34.8 weeks. No significant differences were observed in urinary biomarker levels between the groups at one and 2 months posttreatment. Serum VEGF levels were higher in the treated group than in the nontreated group after IVR.
CONCLUSION: IVR treatment did not show the sustained renal injury or suppress serum VEGF levels in preterm infants with ROP.